Диссертация (1139499), страница 44
Текст из файла (страница 44)
– 2007. – Vol.72. – P.464-472.254. Ellison K.E. Androgen Regulation of Rat Renal Angiotensinogen MessengerRNA Expression./ Ellison K.E. [et al]//J Clin Invest. – 1989. - Vol.83. – P.1941-5.255. Eng J. Adverse Left Ventricular Remodeling and Age Assessed with Cardiac MRImaging: The Multi-Ethnic Study of Atherosclerosis./ Eng J. [et al]// Radiology. – 2015.279-Publishedonline5Nov2015.Availableathttp://pubs.rsna.org/doi/abs/10.1148/radiol.2015150982 29.02.2016256. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogeneticand clinical implication./ Epstein M.
// Am J Kidney Dis. – 2001. – Vol. 37. - №4. – P.1791-1798.257. Eriksen B.O. The progression of chronic kidney disease: a 10-year populationbased study of the effects of gender and age./ Eriksen B.O., Ingebretsen O.C. // KidneyInt. – 2006. – Vol. 69. – №2. – P. 375-382.258. Erman A. Ovarian angiotensin-converting enzyme activity in humans:relationship to estradiol, age, and uterine pathology./ Erman A. [et al]// J EndocrinolMetab. – 1996. – Vol.81. – P.1104-7259.
ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force forthe management of dyslipidaemias of the European Society of Cardiology (ESC) andthe European Atherosclerosis Society (EAS)./ Eur Heart J. – 2011. – Vol.32(14). –P.1769-1818.260. Esler M. Sympathetic nervous system and insulin resistance: From obesity todiabetes./ Esler M. [et al]// Am J Hypertension 2001; 14: 304S-309S.261. Esper R.J. Endothelial dysfunction: a comprehensive appraisal./ Esper R.J. [etal]// Cardiovasc Diabetology.
– 2006. – Vol.5. – P.4-22.262. Estrogen and progestogen use in postmenopausal women: 2010 positionstatement of The North American Menopause Society.// Menopause. – 2010. –Vol.17(2). – P.242-55.263. Färbom P. Interaction between renal function and microalbuminuria forcardiovascular risk in hypertension: the Nordic diltiazem study./ Färbom P. [et al].//Hypertension. – 2008. – Vol.52(1).
– P.115-22264. Feletou M. Endothelial dysfunction: a multifaceted disorder (The Wiggers AwardLecture)./ Feletou M, Vanhoutte PM. // Am J Physiol Heart Circ Physiol. – 2006. –Vol.291. – P.H985–1002.280265. Filer J.S. Leptin resistance and obesity./ Filer J.S. // Presented at the 60-thscientific sessions of the American diabetes association. - June 13, 2000.
- San-Antonio,Tehas, USA.266. Fisman E.Z. Systemic hypertension in postmenopausal women: a clinicalapproach./ Fisman E.Z., Tenenbaum A., Pines A.// Curr Hypertens Rep. – 2002. –Vol.4(6). – P.464-70.267. Florez H. C–reactive protein is elevated in obese patients with the metabolicsyndrome. / Florez H. [et al]// Diabetes Res Clin Pract. – 2006. – Vol.71(1). – P.92–100.268. Folkow B. Pathophysiology of hypertension: differences between young andelderly./ Folkow B. // J Hypertens. – 1993.
– Vol.11( Suppl 4). – P. S21-S24.269. Folsom AR. Prospective study of coronary heart disease incidence in relation tofasting total homocysteine, related genetic polymorphisms, and B vitamins. TheAtherosclerosis Risk in Communities (ARIC) Study./ Folsom AR. [et al]// Circulation.– 1998. – Vol.98. – P.204–210.270. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome amongUS adults: findings from the Third National Health and Nutrition Examination Survey./Ford E.S., Giles W.H., Dietz W.H.
// JAMA. – 2002. – Vol.287. – P.356-9.271. Ford ES. Prevalence of the metabolic syndrome defined by the InternationalDiabetes Federation among adults in the U.S./ Ford ES. // Diabetes Care. – 2005. –Vol.28. – P.2745–9.272. Forte P. Evidence for a difference in nitric oxide biosynthesis between healthywomen and men./ Forte P.
[et al]// Hypertension. – 1998. – Vol.32. – P.730-734.273. Fortepiani L. A. Characterization of an animal model of postmenopausalhypertension in SHR./ Fortepiani L. A. [et al]// Hypertension. - 2003. - Vol. 41. - P.460– 463,274. Fruzzetti F.
Hyperandrogenemia influences the prevalence of the metabolicsyndrome abnormalities in adolescents with the polycystic ovary syndrome./ FruzzettiF. [et al] // Gynecol Endocrinol. - 2009. - 25(5). - 335-43.281275. Fujimoto N. Effects of sex and hypertension subtype on haemodynamics and leftventricular diastolic function in older patients with stage 1 hypertension./ Fujimoto N.[et al]// J Hypertens. – 2013. – Vol.31(11). – P.2282-9276. Gambineri A. Obesity and the polycystic ovary syndrome./ Gambineri A.
[et al] //Int J Obes Relat Metab Disord. - 2002. – Vol.26(7). – P.883-96.277. Ganau A. Patterns of left ventricular hypertrophy and geometric remodeling inessential hypertension./ Ganau A. [et al]// J Am Coll Cardiol. – 1992. – Vol.19. –P.1559-60.278. Gangar K.F. Pulsatility index in internal carotid artery in relation to transdermaloestradiol and time since menopause./ Gangar K.F. [et al]// Lancet. -1991. – Vol.338. –P.939-42.279. Gebhard C. Age- and Gender-Dependent Left Ventricular Remodeling./ GebhardC.
[et al].// Echocardiography. – 2013. – Vol.30(10). – P.1143-50.280. Gerhard M. Aging progressively impairs endothelium-dependent vasodilation inforearm resistance vessels of humans./ Gerhard M. [et al]// Hypertension. – 1996. –Vol.27. – P.849–53.281. Ghasemi A. Nitric oxide and clustering of metabolic syndrome components inpediatrics/ Ghasemi A. [at al.]//Eur J Epidemiol. – 2010.
– Vol.25(1). - P.45-53.282. Ghasemi A. Reference values for serum nitric oxide metabolites in an adultpopulation./ Ghasemi A, Zahedias S, Azizi F./ Clin Biochem. – 2010. – Vol.43(1-2). –P.89-94.283. Ghasemi A. Serum nitric oxide metabolite levels in a general healthy population:relation to sex and age./ Ghasemi A. [et al]// Life Sci. – 2008. – Vol.83(9-10). – P.32631.284.
Gleerup G. Decreased fibrinolytic activity and increased platelet function inhypertension: possible influence of calcium antagonists./ Gleerup G, Winther K. // Am JHypertens. – 1991. – Vol.4. – P.168S-171S285. Golan E. Reduction in Resting Metabolic Rate and Ratio of Plasma Leptin toUrinary Nitric Oxide: Influence on Obesity-Related Hypertension./ Golan E. [et al]//IMAJ. – 2002.
– Vol.4. – P.426-430282286. Grassy G. How to assess sympathetic activity in humans./ Grassy G., Esler M. // JHypertens. – 1999. – Vol.17. – P.719-734.287. Greiten LE. Should there be sex-specific criteria for the diagnosis and treatmentof heart failure?/ Greiten LE. [et al]// J Cardiovasc Transl Res.
– 2014. – Vol.7(2). –P.139-55.288. Grekin R.J. Acetylcholin, γ-aminobutyric acid, serotonin, adenosine, andendogenous ouabain./ Grekin R.J., Hamlyn J.M.// Hypertension primer. The essentialsof high blood pressure. Ed. J.L.Izzo, and H.R.Black./ American Heart Association. –2003. – P.47-49.289.
Halimi J. M. Effects of current smoking and smoking discontinuation on renalfunction and proteinuria in the general population./ Halimi J. M. [et al]// Kidney Int. –2000. – Vol.58. – Р. 1285-1292.290. Halimi J.M. The risk of hypertension in men: direct and indirect effects ofchronic smoking./Halimi J.
M. [et al]// J Hypertension. – 2002. – Vol.20. – P.187-93.291. Hammond I.W. The prevalence and correlates of echocardiographic leftventricular hypertrophy among employed patients with uncomplicated hypertension./Hammond I.W. [et al]// J Am Coll Cardiol.
– 1986. – Vol.7. – P.639-50.292. Haroun NK. Risk factors for chronic kidney disease: a prospective study of23.534 men and women in Washington Country, Maryland./ Haroun NK. [et al]// J AmSoc Nephrol. – 2003. – Vol.14. – P.2934-2941.293. Harrison-Bernard LM. Postovariectomy hypertension is linked to increased renalAT1 receptor and salt sensitivity./ Harrison-Bernard LM, Schulman IH, Raij L. //Hypertension. – 2003.
– Vol.42(6). – P.1157–1163.294. Harshfield GA. Ambulatory blood pressure recordings in children andadolescents./ Harshfield GA. [et al]// Pediatrics. – 1994. – Vol.94. – P.180-184.295. Hartmann B.W. Androgen Serum Levels in Women With Premature OvarianFailure Compared to Fertile and Menopausal Controls./ Hartmann B.W. [et al]//Gynecol Obstet Invest. – 1997. – Vol.44.
– P.127-31.296. Hawkins R.I. Smoking, platelets and thrombosis./ Hawkins R.I. //Nature. – 1972.– Vol. 236. – P. 450 – 452.283297. Haynes W. G. Sympathetic and cardiorenal actions of leptin./ Haynes W. G. [etal]// Hypertension. – 1997. – Vol.30. – P.619-23.298. Hayward C. Gender-Related Differences in the Central Arterial PressureWaveform./ Hayward C, Raymond K. // JACC. – 1997.
– Vol.30(7). – P.1863–71.299. HaywardCS.Gender-relateddifferencesinleftventricularchamberfunction./Hayward CS, Kalnins WV, Kelly RP.//Cardiovasc Res. – 2001. – Vol.49 (2).– P.340–350.300. Hemmelgarn BR. Progression of kidney dysfunction in the community-dwellingelderly./ Hemmelgarn BR. [et al]// Kidney Int. – 2006. - Vol.69. – P.2155–2161.301. Henriksson P. Profound decrease of in vivo formation of thromboxane duringoestrogen therapy./ Henriksson P., Stege R., Green K.
// Eur J Clin Invest. - 1996. –Vol.26(12). – P.1186-8.302. Hermida RC. 2013 ambulatory blood pressure monitoring recommendations forthe diagnosis of adult hypertension, assessment of cardiovascular and otherhypertension-associated risk, and attainment of therapeutic goals./ Hermida RC. [etal].// Chronobiol Int.
– 2013. – Vol.30(3). – P.355-410.303. Hermida RC. Differences between men and women in ambulatory blood pressurethresholds for diagnosis of hypertension based on cardio- vascular outcomes./ HermidaRC. [et al]// Chronobiol. Int. – 2013. – Vol.30. – P. 221–232.304. Hermida RC. Differences Between Men and Women in Ambulatory BloodPressure Thresholds for Diagnosis of Hypertension Based on CardiovascularOutcomes./ Hermida RC. [et al]// Chronobiol Int – 2013. – Vol.30(1-2). – P.221-32.305.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
